AUSTIN, Texas, March 27 (Reuters) - A Texas judge on Tuesday finalized a $158 million agreement to settle a lawsuit that accused Johnson & Johnson of improperly marketing its Risperdal anti-psychotic drug to state residents in the Medicaid program.
The action in Austin by state District Judge John Dietz paves the way for Johnson & Johnson to pay the money to the original plaintiff, his attorneys, the state of Texas and the federal government. It’s the largest fraud recovery ever in Texas for Medicaid, the federal-state health insurance program for low-income people.
“We are pleased that the settlement agreement has been brought to a close,” Teresa Mueller, a spokeswoman for J&J’s Janssen Pharmaceuticals unit, said on Tuesday. “Janssen is committed to ethical business practices, and has policies in place to ensure its products are only promoted for their FDA-approved indications.”
The $158 million is the same amount that Johnson & Johnson said in January that it would pay. Since then, the parties have quibbled over the distribution of the money, according to Allen Jones, who raised the red flag about J&J’s marketing practices while working with the state of Pennsylvania.
Johnson & Johnson declined comment on the discussions.
“The defendants wanted to have more of a say than they did on how the monies were allocated,” Tom Melsheimer, a lawyer for Jones, told Reuters on Tuesday.
Of the $158 million, about 31 percent will go to the federal government, 40 percent to the state of Texas, 17 percent to Jones and the rest (roughly 12 percent) is for attorneys’ fees, according to Tommy Jacks, a lawyer for Jones.
The settlement will fully resolve all Risperdal-related claims in Texas, Mueller said. The agreement is specific to Texas and does not involve other state or federal Risperdal litigation.
The deal marked the first Risperdal settlement with any U.S. state. It settles claims brought by Texas in 2004 involving alleged Medicaid overpayments during the years 1994 to 2008.
Jones said on Sunday that Johnson & Johnson was trying to reduce the amount that he received in what he characterized as an effort to discourage whistleblowers.
Under state law, Jones was entitled to receive between 15 and 25 percent of the settlement, said Tom Kelley, a spokesman for Texas Attorney General Greg Abbott.
Jones said on Tuesday that the 17 percent he is getting is “far, far more” than what Johnson & Johnson wanted to pay but that “this has never been about the bucks.”
“I have done all that I can to expose Johnson & Johnson,” Jones told Reuters on Tuesday.
Kelley said that Texas officials “are completely happy” with the settlement and that Texas taxpayers are receiving a larger allocation than initially planned.
Our Standards: The Thomson Reuters Trust Principles.